Author's response to reviews

Title: Chinese Acute Ischemic Stroke Treatment Outcome Registry (CASTOR): protocol for a prospective registry study on patterns of real-world treatment of acute ischemic stroke in China

Authors:

Weiping Sun (swp_222@163.com)

Qianhua Ou (ouqh@techpool.com.cn)

Zhijun Zhang (zhangzj@techpool.com.cn)

Jiazhi Qu (Clare.qu@techpool.com.cn)

Yining Huang (huangyining_99@126.com)

Version: 3 **Date:** 10 Jun 2017

Author's response to reviews:

Associate Editor's comment:

One of the concern is the quality control of such big trial. Can I suggest to have a Data auditor Team to monitor the data management?

No other suggestions.

Author's response: We thanks for associate editor's comment a lot. We agree with associate editor's point. As descried in our manuscript, CASTOR is a registry study with a large sample size. It is critical to ensure the data quality. As suggested, we have revised related sentences in page 10 of our manuscript. "Before the initiation of the study, the research staffs undertaking the outcome measurement are trained in use of the data collections tools, assessments and reporting procedures. A data audit team will monitor the data management. During the study, site audit visits by the sponsor and a third-party Contract Research Organization (CRO) will occur on a regular basis to ensure adherence to study documentation, reporting procedures and study protocol. eCRF will be reviewed to ensure the data collected accurately. All data management and supervising procedures must be in accordance to company Standard Operation Procedures (SOPs) for Good Clinical Practice (GCP) Guidelines (Seen in supplementary file)." Please do not hesitate to contact me if you have any questions.